Perrigo (PRGO) is up 1.7% after announcing it has filed for a new drug application with the FDA for its Androgel testosterone gel, which currently generates $900M in annual worldwide sales. However, Perrigo adds that Abbott (ABT) has filed a patent infringement suit against it over the product.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs